BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Reference Citation Analysis]
2 Jang EJ, Ha JE, Im SG, Kim MG, Sohn HS. A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease. Clin Drug Investig 2019;39:625-30. [DOI: 10.1007/s40261-019-00784-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jeon SR. Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis? Intest Res 2018;16:163-5. [PMID: 29743828 DOI: 10.5217/ir.2018.16.2.163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy? Intest Res 2017;15:263-5. [PMID: 28670224 DOI: 10.5217/ir.2017.15.3.263] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Ha JE, Jang EJ, Im SG, Sohn HS. Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014). Korean J Clin Pharm 2019;29:79-88. [DOI: 10.24304/kjcp.2019.29.2.79] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
6 Lee WS, Azmi N, Ng RT, Ong SY, Ponnampalavanar SS, Mahadeva S, Hilmi I. Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. Intest Res 2017;15:524-8. [PMID: 29142521 DOI: 10.5217/ir.2017.15.4.524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Kim YS. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Korean J Gastroenterol 2018;71:74-80. [PMID: 29471604 DOI: 10.4166/kjg.2018.71.2.74] [Reference Citation Analysis]
8 de-León-Rendón J, López-pérez R, Gracida-mancilla N, Jiménez-bobadilla B, Alarcón-bernés L, Mendoza-ramírez S, Villanueva-herrero J. The controlling nutritional status score: A promising tool for nutritional screening and predicting severity in ulcerative colitis patients. Revista de Gastroenterología de México (English Edition) 2021;86:110-7. [DOI: 10.1016/j.rgmxen.2020.05.007] [Reference Citation Analysis]
9 Park YE, Park Y, Park SJ, Kim TI, Kim WH, Kim JN, Lee NR, Cheon JH. Is fasting beneficial for hospitalized patients with inflammatory bowel diseases? Intest Res 2020;18:85-95. [PMID: 31308352 DOI: 10.5217/ir.2019.00055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kutsuna R, Miyoshi-Akiyama T, Tomida J, Kawamura Y. Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678T, Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis. Microbiol Resour Announc 2021;10:e0078021. [PMID: 34528815 DOI: 10.1128/MRA.00780-21] [Reference Citation Analysis]
11 Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Pak S, Hwang SW, Shim IK, Bae SM, Ryu YM, Kim HB, Do EJ, Son HN, Choi EJ, Park SH, Kim SY, Park SH, Ye BD, Yang SK, Kanai N, Maeda M, Okano T, Yang DH, Byeon JS, Myung SJ. Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats. Sci Rep 2018;8:11314. [PMID: 30054522 DOI: 10.1038/s41598-018-29617-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ferrante C, Recinella L, Ronci M, Orlando G, Di Simone S, Brunetti L, Chiavaroli A, Leone S, Politi M, Tirillini B, Angelini P, Covino S, Venanzoni R, Vladimir-Knežević S, Menghini L. Protective effects induced by alcoholic Phlomis fruticosa and Phlomis herba-venti extracts in isolated rat colon: Focus on antioxidant, anti-inflammatory, and antimicrobial activities in vitro. Phytother Res 2019;33:2387-400. [PMID: 31322313 DOI: 10.1002/ptr.6429] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1166-74. [PMID: 30672608 DOI: 10.1111/jgh.14609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 de-León-Rendón JL, López-Pérez RY, Gracida-Mancilla NI, Jiménez-Bobadilla B, Alarcón-Bernés L, Mendoza-Ramírez S, Villanueva-Herrero JA. The controlling nutritional status score: A promising tool for nutritional screening and predicting severity in ulcerative colitis patients. Rev Gastroenterol Mex (Engl Ed) 2021;86:110-7. [PMID: 33261942 DOI: 10.1016/j.rgmx.2020.05.012] [Reference Citation Analysis]
16 Ling FM, Lu FN, Wang SN, Zhu LR. Efficacy and safety of Etiasa for treatment of mild-to-moderate ulcerative colitis: A Meta-analysis. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 880-892 [DOI: 10.11569/wcjd.v29.i15.880] [Reference Citation Analysis]
17 Magalhães DA, Batista JA, Sousa SG, Ferreira JDS, da Rocha Rodrigues L, Pereira CMC, do Nascimento Lima JV, de Albuquerque IF, Bezerra NLSD, Monteiro CEDS, Franco AX, da Costa Filho HB, Ferreira FCS, Havt A, Di Lenardo D, Vasconcelos DFP, de Oliveira JS, Soares PMG, Barbosa ALDR. McN-A-343, a muscarinic agonist, reduces inflammation and oxidative stress in an experimental model of ulcerative colitis. Life Sci 2021;272:119194. [PMID: 33609541 DOI: 10.1016/j.lfs.2021.119194] [Reference Citation Analysis]
18 Kim ES, Lee HS, Kim SK, Kim EY, Jang BI, Kim KO, Yang CH, Lee YJ; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol 2020;55:163-8. [PMID: 31984815 DOI: 10.1080/00365521.2020.1714716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lee KM. [Monitoring Disease Activity: How and When?]. Korean J Gastroenterol 2018;71:69-73. [PMID: 29471603 DOI: 10.4166/kjg.2018.71.2.69] [Reference Citation Analysis]
20 Lee HH, Bae JM, Lee B, Lee K, Wie JH, Kim JS, Cho Y, Jung S, Kim SW, Choi H, Choi M. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther 2020;51:861-9. [DOI: 10.1111/apt.15654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211024769. [PMID: 34285716 DOI: 10.1177/17562848211024769] [Reference Citation Analysis]
22 Yoon H, Lee DH, Lee YH, Jeong JC, Lee ST, Choi MG, Jeon SW, Shim KN, Baik GH, Kim JG, Moon JS, Sung IK, Lee SK, Rhee PL, Jung HY, Lee BE, Kim HS, Kim SG, Lee KM, Seong JK, Jang JS, Park JJ. Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial. Gut Liver 2018;12:516-22. [PMID: 29938452 DOI: 10.5009/gnl17416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
23 Jena A, Mishra S, Singh AK, Sekar A, Sharma V. Cytomegalovirus in ulcerative colitis: An evidence-based approach to diagnosis and treatment. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032662] [Reference Citation Analysis]
24 Park SK, Park SH, Eun CS, Seo GS, Im JP, Kim TO, Park DI. Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intest Res 2019;17:349-56. [PMID: 30727712 DOI: 10.5217/ir.2018.00064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Cheon JH. Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists. J Rheum Dis 2021;28:4-16. [DOI: 10.4078/jrd.2021.28.1.4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee KH, Kim JO, Lee JS, Ko BM, Park S. The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. Intest Res 2021;19:62-70. [PMID: 32375208 DOI: 10.5217/ir.2019.09156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20-7. [PMID: 29223139 DOI: 10.3904/kjim.2017.393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
29 Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol 2019; 25(8): 989-1001 [PMID: 30833804 DOI: 10.3748/wjg.v25.i8.989] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kim DB, Lee KM, Park SH, Kim YS, Kim ES, Lee J, Jung SA, Seo GS, Lee JM. Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea. Intest Res 2018;16:267-72. [PMID: 29743839 DOI: 10.5217/ir.2018.16.2.267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Recinella L, Chiavaroli A, Ronci M, Menghini L, Brunetti L, Leone S, Tirillini B, Angelini P, Covino S, Venanzoni R, Zengin G, Di Simone S, Ciferri MC, di Giacomo V, Cataldi A, Rapino M, Valerio VD, Orlando G, Ferrante C. Multidirectional Pharma-Toxicological Study on Harpagophytum procumbens DC. ex Meisn.: An IBD-Focused Investigation. Antioxidants (Basel) 2020;9:E168. [PMID: 32085616 DOI: 10.3390/antiox9020168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Castro-poceiro J, Fernández-clotet A, Panés J. Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. Immunotherapy 2018;10:1203-17. [DOI: 10.2217/imt-2018-0099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jeon SR, Chai J, Kim C, Lee CH. Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation. Curr Infect Dis Rep 2018;20:21. [PMID: 29804272 DOI: 10.1007/s11908-018-0627-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
34 Choi YI, Kim YJ, Chung JW, Kim KO, Kim H, Park RW, Park DK. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform 2020;8:e15124. [PMID: 32293578 DOI: 10.2196/15124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Song EM, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33783045 DOI: 10.1111/jgh.15508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Jeong KM, Seo JY, Kim A, Baek YS, Song HJ, Jeon J. Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature. Ann Dermatol 2021;33:82-5. [PMID: 33911817 DOI: 10.5021/ad.2021.33.1.82] [Reference Citation Analysis]
37 Park SB, Kim S, Lee J, Lee YJ, Baek DH, Seo GS, Kim ES, Kim S, Kim SY. Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02178-0] [Reference Citation Analysis]